Reliq Health Announces Community Care Pilot with the United Kingdom (UK) National Health Service

VANCOUVER, British Columbia, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) (OTCQB:RQHTF) (“Reliq” or the “Company”), a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community-Based Healthcare, is pleased to announce that it has been accepted into the National Health Service (NHS) United Kingdom’s (UK’s) Test Beds program and will begin piloting its virtual care technology with a London-area hospital in Q4 2016.

“We are very excited to be piloting Reliq’s community care platform in the UK. Our technology is strongly aligned with the NHS England’s ongoing initiative to improve the management of long term conditions in the community,” said Dr. Lisa Crossley, CEO of Reliq Health. “Our platform uses a high tech, low touch approach to provide high quality healthcare in the home, reducing exacerbations and disease-related complications, decreasing healthcare costs and enhancing patient and family satisfaction.  We look forward to participating in the NHS Test Beds program to demonstrate the value of Reliq Health’s technology to patients, caregivers and the health system in the UK.”

The pilot will focus on two of the most common chronic conditions in the UK, congestive heart failure (CHF) and diabetes.  Currently there are over 15 million people in England living with at least one long-term health condition. In addition to the impact on people’s lives, long-term condition management accounts for half of all General Practitioner appointments and 70% of hospital bed days in the UK.  Reliq Health’s proprietary hardware and software supports patients and their caregivers in the home, providing remote vitals monitoring with alerts to clinicians as needed, audible reminders to improve patient compliance with prescribed medication regimens and lifestyle changes, tailored patient education and secure communication with the entire care team.


“Dr. Lisa Crossley”

CEO and Director

For further information: CORE Capital Partners at 604-566-9233 or

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws.  All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. 

Reliq Health Technologies Inc. (the "Company") does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company's historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.